

In the claims:

1-25. (Cancelled)

26. (Previously amended) A stable, dry powder insulin composition for delivery to the alveolar regions of the lungs, the composition produced by a method comprising:
dissolving insulin in an aqueous buffer at a concentration in the range from 0.01% to 1% to form a solution;
adding a pharmaceutical carrier to the solution; and
spray drying the solution to produce substantially amorphous particles having an average size in the range from 0.1 μm to 5 μm , wherein insulin is present in the particles at from 15% to 80% by weight.

27. (Cancelled)

28. (Previously amended) An insulin composition produced by a method as in claim 26, wherein the pharmaceutical carrier is a carbohydrate, organic salt, amino acid, peptide, or protein which produces a powder upon spray drying.

29. (Previously presented) An insulin composition produced by a method as in claim 28, wherein the pharmaceutical carrier is a carbohydrate selected from the group consisting of mannitol, raffinose, lactose, malto dextrin and trehalose.

30. (Previously presented) An insulin composition produced by a method as in claim 28, wherein the pharmaceutical carrier is an organic salt selected from the group consisting of sodium citrate, sodium acetate, and sodium ascorbate.

31. (Previously amended) A stable, dry powder insulin composition for delivery to the alveolar regions of the lungs, the composition produced by a method comprising:
dissolving insulin in an aqueous buffer at a concentration in the range from 0.01% to 1% to form a solution;
adding a pharmaceutical carrier to the solution; and
spray drying the solution to produce substantially amorphous particles having an average size below 10 μm , wherein insulin is present in the particles at from 15% to 80% by weight.

32. (Cancelled)

33. (Previously amended) An insulin composition produced by a method as in claim 31, wherein the pharmaceutical carrier is a carbohydrate, organic salt, amino acid, peptide, or protein which produces a powder upon spray drying.

34. (Previously amended) An insulin composition produced by a method as in claim 33, wherein the pharmaceutical carrier is a carbohydrate selected from the group consisting of mannitol, raffinose, lactose, malto dextrin and trehalose.

35. (Previously presented) An insulin composition produced by a method as in claim 33, wherein the pharmaceutical carrier is an organic salt selected from the group consisting of sodium citrate, sodium acetate, and sodium ascorbate.